LinkedIn·Wednesday, 24 June 2026·24 Jun 2026
another significant milestone for Agomab today. The company announces the design of its NOV-ERA Phase 2b study in Fibrostenosing Crohn's…
V-Bio Ventures
5,319 followers
another significant milestone for Agomab today. The company announces the design of its NOV-ERA Phase 2b study in Fibrostenosing Crohn's Disease. This will be the first time a drug is tested in this indication, with a fit for purpose endpoint. Great to see our portfolio company forging ahead and exploring new territory!
↻ 2
View on LinkedIn Cross-referenced
Related on the wire
Our colleagues Christina Takke and Katja Rosenkranz will be attending Biocentury Grand Rounds on September 23rd-25th. Join us to discuss…
V-Bio Ventures portfolio company Tanai Therapeutics just announced the appointment of Josua Jordi as its new CEO. We are excited to welcome…
Our partners Shelley Margetson and 🧪 Ward Capoen will be attending IPEM Global in Paris next month. Come say hello and learn about V-Bio…
Setra returns to operating profit in Q2 Lower timber costs and efficiency gains helped the Swedish wood-products company improve sharply.…
No one facing cancer should have to choose between their healthcare and daily needs. We're working to change this heartbreaking reality.…
When AI takes over the world: it will still need people - to produce electricity, as in the Matrix. Unless it switches to gas. Then AI will…